Know Cancer

or
forgot password

High Dose Chemotherapy and Autologous or Allogeneic Blood Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma


Phase 2
18 Years
65 Years
Not Enrolling
Both
Low Grade Lymphoma

Thank you

Trial Information

High Dose Chemotherapy and Autologous or Allogeneic Blood Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma


Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem
cell transplanation if they have an HLA matched sibling, or an autologous transplant if they
do not.


Inclusion Criteria:



- indolent histology lymphomas after relapse 1 or 2 LVEF > 50% Creatinine < 150 umol/L
bilirubin < 30 umol/L wbc >3.5X10^9/L platelets >100X10^9/L other medical condition
as controlled

Exclusion Criteria:

- pregnant lactating HIV positive CNS involvement by lymphoma other malignancy

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

feasibility

Principal Investigator

Doug Stewart

Investigator Role:

Principal Investigator

Investigator Affiliation:

Alberta Cancer Board - TBCC

Authority:

Canada: Health Canada

Study ID:

147

NCT ID:

NCT00144092

Start Date:

May 2001

Completion Date:

June 2010

Related Keywords:

  • Low Grade Lymphoma
  • autologous and allogeneic stem cell transplantation
  • low grade lymphoma
  • mantle cell
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location